FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average	burden				
ours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response													
1. Name and Address of Reporting Person* MEYER ALAN R			2. Issuer Name and Ticker or Trading Symbol Ocuphire Pharma, Inc. [OCUP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) C/O OCUPHIRE PHARMA, INC., 37000 GRAND RIVER AVE, SUITE 120			3. Date of Earliest Transaction (Month/Day/Year) 11/11/2020						Officer (giv	ve title below)	Oth	er (specify below	v)	
(Street) FARMINGTON HILLS, MI 48335			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acqu				ies Acquire	lired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year		A. Deemed xecution Date, if my Month/Day/Year)			4. Securities Acquir (A) or Disposed of ((Instr. 3, 4 and 5)			/		Ownership Form:	7. Nature of Indirect Beneficial Ownership
				·	• .		ode V	Amount (A) o	r Price	(Instr. 3 and 4)			or Indirect (I) (Instr. 4)	(Instr. 4)
Reminder:								ns who respo ned in this fo						474 (9-02)
							contai form o	ned in this fo lisplays a cur oosed of, or Be	orm are not rently vali	t required d OMB co	to respon	d unless the		474 (9-02)
1. Title of	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transact	s, calls, was 5. Nu tion of Deriv) Secur Acqu (A) o Dispo	mber rative rities ired rosed) . 3, 4,	form c quired, Disp s, options, c	ned in this for isplays a curbosed of, or Be convertible secretisable and Date	orm are not rently vali neficially O urities)	t required d OMB co	to respon ntrol num	d unless the	f 10. Ownersh Form of Derivativ Security: Direct (E or Indirec	11. Nature of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact	s, calls, was 5. Nu tion of Deriv Secur Acqu (A) of Dispo of (D (Instr	mber rative rities ired rosed) . 3, 4,	quired, Disp s, options, c 6. Date Ex Expiration	ned in this folisplays a cui lisplays a cui loosed of, or Be convertible secuercisable and Date y/Year)	rently vali neficially O urities) 7. Title an of Underly Securities	t required d OMB co	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivativ Security: Direct (E or Indirects) (I)	11. Nature of Indire Benefici Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
MEYER ALAN R C/O OCUPHIRE PHARMA, INC. 37000 GRAND RIVER AVE, SUITE 120 FARMINGTON HILLS, MI 48335	X				

Signatures

/s/ Emily J. Johns, by Power of Attorney	11/13/2020
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) Vesting in 12 equal monthly increments beginning on November 30, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.